



Universiteit
Leiden
The Netherlands

Breathing in thin air: structure, function and therapeutic opportunities of bd type oxidases

Velden, T.T. van der

Citation

Velden, T. T. van der. (2026, September 2). *Breathing in thin air: structure, function and therapeutic opportunities of bd type oxidases*. Retrieved from <https://hdl.handle.net/1887/4309020>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4309020>

Note: To cite this publication please use the final published version (if applicable).

References

1. Naghavi M, Vollset SE, Ikuta KS, Swetschinski LR, Gray AP, Wool EE, et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. *The Lancet*. 2024 Sep;404(10459):1199–226. doi:10.1016/S0140-6736(24)01867-1
2. WHO. GLOBAL TUBERCULOSIS REPORT 2021. 2021.
3. Silva S, Arinaminpathy N, Atun R, Goosby E, Reid M. Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis. *Lancet Glob Health*. 2021 Oct 1;9(10):e1372–9. doi:10.1016/S2214-109X(21)00299-0 PubMed PMID: 34487685.
4. Silver LL. Challenges of antibacterial discovery. *Clin Microbiol Rev*. 2011 Jan;24(1):71–109. doi:10.1128/CMR.00030-10 PubMed PMID: 21233508.
5. Hutchings M, Truman A, Wilkinson B. Antibiotics: past, present and future. *Curr Opin Microbiol*. 2019 Oct 1;51:72–80. doi:10.1016/j.mib.2019.10.008 PubMed PMID: 31733401.
6. Uddin TM, Chakraborty AJ, Khusro A, Zidan BRM, Mitra S, Emran T Bin, et al. Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects. *J Infect Public Health*. 2021 Dec 1;14(12):1750–66. doi:10.1016/j.jiph.2021.10.020 PubMed PMID: 34756812.
7. Bush K, Bradford PA. β -lactams and β -lactamase inhibitors: An overview. *Cold Spring Harb Perspect Med*. 2016 Aug 1;6(8). doi:10.1101/cshperspect.a025247 PubMed PMID: 27329032.
8. Doménech-Sánchez A, Martínez-Martínez L, Hernández-Allés S, Conejo M del C, Pascual Á, Tomás JM, et al. Role of *Klebsiella pneumoniae* OmpK35 porin in antimicrobial resistance. *Antimicrob Agents Chemother*. 2003 Oct 1;47(10):3332–5. doi:10.1128/AAC.47.10.3332-3335.2003 PubMed PMID: 14506051.
9. Arenz S, Nguyen F, Beckmann R, Wilson DN. Cryo-EM structure of the tetracycline resistance protein TetM in complex with a translating ribosome at 3.9-Å resolution. *Proc Natl Acad Sci U S A*. 2015 Apr 28;112(17):5401–6. doi:10.1073/pnas.1501775112 PubMed PMID: 25870267.
10. Miller WR, Tran TT, Diaz L, Rios R, Khan A, Reyes J, et al. LiaR-independent pathways to daptomycin resistance in *Enterococcus faecalis* reveal a multilayer defense against cell envelope antibiotics. *Mol Microbiol*. 2019 Mar 1;111(3):811–24. doi:10.1111/mmi.14193 PubMed PMID: 30582877.
11. Zalis EA, Nuxoll AS, Manuse S, Clair G, Radlinski LC, Conlon BP, et al. Stochastic variation in expression of the tricarboxylic acid cycle produces persister cells. *mBio*. 2019 Aug 1;10(5). doi:10.1128/mBio.01930-19 PubMed PMID: 31530676.
12. Hards K, Cook GM. Targeting bacterial energetics to produce new antimicrobials. *Drug Resistance Updates*. 2018 Jan 1;36:1–12. doi:10.1016/j.drug.2017.11.001 PubMed PMID: 29499834.
13. Hasenoehrl EJ, Wiggins TJ, Berney M. Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in *Mycobacterium tuberculosis*. *Front Cell Infect Microbiol*. 2021 Jan 11;10. doi:10.3389/fcimb.2020.611683 PubMed PMID: 33505923.
14. Lobritz MA, Belenky P, Porter CBM, Gutierrez A, Yang JH, Schwarz EG, et al. Antibiotic efficacy is linked to bacterial cellular respiration. *Proc Natl Acad Sci U S A*. 2015 Jul 7;112(27):8173–80. doi:10.1073/pnas.1509743112 PubMed PMID: 26100898.
15. Stokes JM, Lopatkin AJ, Lobritz MA, Collins JJ. Bacterial Metabolism and Antibiotic Efficacy. *Cell Metab*. 2019 Aug 6;30(2):251–9. doi:10.1016/j.cmet.2019.06.009 PubMed PMID: 31279676.
16. Sharma P, Teixeira De Mattos MJ, Hellingwerf KJ, Bekker M. On the function of the various quinone species in *Escherichia coli*. In: *The FEBS Journal*. 2012. p. 3364–73. doi:10.1111/j.1742-4658.2012.08608.x PubMed PMID: 22521170.

17. van Beilen JWA, Hellingwerf KJ. All three endogenous quinone species of *Escherichia coli* are involved in controlling the activity of the aerobic/anaerobic response regulator ArcA. *Front Microbiol.* 2016 Sep 7;7(1339). doi:10.3389/fmicb.2016.01339
18. Udden G, Bongaerts J. Alternative respiratory pathways of *Escherichia coli*: energetics and transcriptional regulation in response to electron acceptors. *Biochim Biophys Acta.* 1997;1320:217–34. doi:10.1016/S0005-2728(97)00034-0
19. Li K, Schurig-Briccio LA, Feng X, Upadhyay A, Pujari V, Lechartier B, et al. Multitarget drug discovery for tuberculosis and other infectious diseases. *J Med Chem.* 2014 Apr 10;57(7):3126–9. doi:10.1021/jm500131s PubMed PMID: 24568559.
20. Hamamoto H, Urai M, Ishii K, Yasukawa J, Paudel A, Murai M, et al. Lysocin e is a new antibiotic that targets menaquinone in the bacterial membrane. *Nat Chem Biol.* 2015 Feb 1;11(2):127–33. doi:10.1038/nchembio.1710 PubMed PMID: 25485686.
21. Yagi A, Uchida R, Hamamoto H, Sekimizu K, Kimura KI, Tomoda H. Anti-Mycobacterium activity of microbial peptides in a silkworm infection model with *Mycobacterium smegmatis*. *J Antibiot.* 2017 May 1;70(5):685–90. doi:10.1038/ja.2017.23 PubMed PMID: 28446822.
22. Vilch ze C, Weinrick B, Leung LW, Jacobs WR. Plasticity of *Mycobacterium tuberculosis* NADH dehydrogenases and their role in virulence. *Proc Natl Acad Sci U S A.* 2018 Feb 13;115(7):1599–604. doi:10.1073/pnas.1721545115 PubMed PMID: 29382761.
23. Mcadam RA, Quan S, Smith DA, Bardarov S, Betts JC, Cook FC, et al. Characterization of a *Mycobacterium tuberculosis* H37Rv transposon library reveals insertions in 351 ORFs and mutants with altered virulence. *Microbiol.* 2002;148:2975–86.
24. Beites T, O'Brien K, Tiwari D, Engelhart CA, Walters S, Andrews J, et al. Plasticity of the *Mycobacterium tuberculosis* respiratory chain and its impact on tuberculosis drug development. *Nat commun.* 2019 Dec 1;10(1). doi:10.1038/s41467-019-12956-2 PubMed PMID: 31672993.
25. Feng X, Zhu W, Schurig-Briccio LA, Lindert S, Shoen C, Hitchings R, et al. Anti-infectives targeting enzymes and the proton motive force. *Proc Natl Acad Sci U S A.* 2015 Dec 22;112(51):E7073–82. doi:10.1073/pnas.1521988112 PubMed PMID: 26644565.
26. Beites T, O'Brien K, Tiwari D, Engelhart CA, Walters S, Andrews J, et al. Plasticity of the *Mycobacterium tuberculosis* respiratory chain and its impact on tuberculosis drug development. *Nat commun.* 2019 Dec 1;10(1). doi:10.1038/s41467-019-12956-2 PubMed PMID: 31672993.
27. Weinstein EA, Yano T, Li LS, Avarbock D, Avarbock A, Helm D, et al. Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. *proc natl Acad Sci.* 2005;22(12):4548–53.
28. Nakatani Y, Shimaki Y, Dutta D, Muench SP, Ireton K, Cook GM, et al. Unprecedented Properties of Phenothiazines Unraveled by a NDH-2 Bioelectrochemical Assay Platform. *J Am Chem Soc.* 2020 Jan 22;142(3):1311–20. doi:10.1021/jacs.9b10254 PubMed PMID: 31880924.
29. Amaral L, Viveiros M. Thioridazine: A non-antibiotic drug highly effective, in combination with first line anti-tuberculosis drugs, against any form of antibiotic resistance of *Mycobacterium tuberculosis* due to its multi-mechanisms of action. *Antibiotics.* MDPI AG; 2017. doi:10.3390/antibiotics6010003
30. Amaral L, Kristiansen JE, Abebe LS, Millett W. Inhibition of the respiration of multi-drug resistant clinical isolates of *Mycobacterium tuberculosis* by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. *Journal of Antimicrobial Chemotherapy.* 1996;38:1049–53.

31. Lamprecht DA, Finin PM, Rahman MA, Cumming BM, Russell SL, Jonnala SR, et al. Turning the respiratory flexibility of *Mycobacterium tuberculosis* against itself. *Nat Commun.* 2016;7. doi:10.1038/ncomms12393 PubMed PMID: 27506290.
32. Lechartier B, Cole ST. Mode of action of clofazimine and combination therapy with benzothiazinones against *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother.* 2015 Aug 1;59(8):4457-63. doi:10.1128/AAC.00395-15 PubMed PMID: 25987624.
33. Reddy VM, O'sullivan JO, Gangadharam PRJ. Antimycobacterial activities of rominophenazines. *Journal of antimicrobial chemotherapy.* 1999;43:615-23.
34. Maklashina E, Cecchini G, Dikanov SA. Defining a direction: Electron transfer and catalysis in *Escherichia coli* complex II enzymes. *Biochim Biophys Acta Bioenerg.* 2013 May;1827(5):668-78. doi:10.1016/j.bbabi.2013.01.010 PubMed PMID: 23396003.
35. Roy C, Lancaster D. Succinate:quinone oxidoreductases: an overview. *Biochim Biophys Acta.* 2002;1-6.
36. Mogi T, Kawakami T, Arai H, Igarashi Y, Matsushita K, Mori M, et al. Siccantin rediscovered as a species-selective succinate dehydrogenase inhibitor. *J Biochem.* 2009;146(3):383-7. doi:10.1093/jb/mvp085 PubMed PMID: 19505951.
37. Eoh H, Rhee KY. Multifunctional essentiality of succinate metabolism in adaptation to hypoxia in *Mycobacterium tuberculosis*. *Proc Natl Acad Sci U S A.* 2013 Apr 16;110(16):6554-9. doi:10.1073/pnas.1219375110 PubMed PMID: 23576728.
38. Mathiyazakan V, Wong CF, Harikishore A, Pethe K, Grüber G. Cryo-Electron Microscopy Structure of the *Mycobacterium tuberculosis* Cytochrome bcc:aa3 Supercomplex and a Novel Inhibitor Targeting Subunit Cytochrome cI. *Antimicrob Agents Chemother.* 2023 Jun 1;67(6). doi:10.1128/aac.01531-22 PubMed PMID: 37158740.
39. Matsoso LG, Kana BD, Crellin PK, Lea-Smith DJ, Pelosi A, Powell D, et al. Function of the cytochrome bc1-aa3 branch of the respiratory network in mycobacteria and network adaptation occurring in response to its disruption. *J Bacteriol.* 2005 Sep;187(18):6300-8. doi:10.1128/JB.187.18.6300-6308.2005 PubMed PMID: 16159762.
40. de Jager VR, Dawson R, van Niekerk C, Hutchings J, Kim J, Vanker N, et al. Telacebec (Q203), a New Antituberculosis agent. *New England Journal of Medicine.* 2020 Mar 26;382(13):1278-80. doi:10.1056/nejmc2001899 PubMed PMID: 32069388.
41. Abrahams KA, Cox JAG, Spivey VL, Loman NJ, Pallen MJ, Constantinidou C, et al. Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting *M. tuberculosis* QcrB. *PLoS One.* 2012 Dec 31;7(12). doi:10.1371/journal.pone.0052951 PubMed PMID: 23300833.
42. Bahuguna A, Rawat S, Rawat DS. QcrB in *Mycobacterium tuberculosis*: The new drug target of antitubercular agents. *Med Res Rev.* 2021 Jul 1;41(4):2565-81. doi:10.1002/med.21779 PubMed PMID: 33400275.
43. Kalia NP, Hasenoehrl EJ, Rahman NBA, Koh VH, Ang MLT, Sajorda DR, et al. Exploiting the synthetic lethality between terminal respiratory oxidases to kill *Mycobacterium tuberculosis* and clear host infection. *Proc Natl Acad Sci U S A.* 2017 Jul 11;114(28):7426-31. doi:10.1073/pnas.1706139114 PubMed PMID: 28652330.
44. Rybniker J, Vocat A, Sala C, Busso P, Pojer F, Benjak A, et al. Lansoprazole is an antituberculous prodrug targeting cytochrome bc 1. *Nat Commun.* 2015 Jul 9;6. doi:10.1038/ncomms8659 PubMed PMID: 26158909.

45. Kana BD, Weinstein EA, Avarbock D, Dawes SS, Rubin H, Mizrahi V. Characterization of the *cydAB*-encoded cytochrome bd oxidase from *Mycobacterium smegmatis*. *J Bacteriol*. 2001;183(24):7076–86. doi:10.1128/JB.183.24.7076–7086.2001 PubMed PMID: 11717265.
46. Belevich I, Borisov VB, Bloch DA, Konstantinov AA, Verkhovsky MI. Cytochrome bd from *Azotobacter vinelandii*: Evidence for high-affinity oxygen binding. *Biochemistry*. 2007;46(39):11177–84. doi:10.1021/bi700862u PubMed PMID: 17784736.
47. D'mello R, Hill S, Poole RK. The cytochrome bd quinol oxidase in *Escherichia coli* has an extremely high oxygen affinity and two oxygen-binding haems: implications for regulation of activity in vivo by oxygen inhibition. *Microbiol*. 1996;142:755–63.
48. Mason MG, Shepherd M, Nicholls P, Dobbin PS, Dodsworth KS, Poole RK, et al. Cytochrome bd confers nitric oxide resistance to *Escherichia coli*. *Nat Chem Biol*. 2009 Feb 6;5(2):94–6. doi:10.1038/nchembio.135 PubMed PMID: 19109594.
49. Al-Attar S, Yu Y, Pinkse M, Hoeser J, Friedrich T, Bald D, et al. Cytochrome bd Displays Significant Quinol Peroxidase Activity. *Sci Rep*. 2016 Jun 9;6. doi:10.1038/srep27631 PubMed PMID: 27279363.
50. Borisov VB, Forte E, Davletshin A, Mastronicola D, Sarti P, Giuffrè A. Cytochrome bd oxidase from *Escherichia coli* displays high catalase activity: An additional defense against oxidative stress. *FEBS Lett*. 2013 Jul 11;587(14):2214–8. doi:10.1016/j.febslet.2013.05.047 PubMed PMID: 23727202.
51. Forte E, Siletsky SA, Borisov VB. In *Escherichia coli* Ammonia Inhibits Cytochrome bo₃ But Activates Cytochrome bd-I. *Antioxidants*. 2020;10(13):1–15. doi:10.3390/antiox
52. Fu H, Chen H, Wang J, Zhou G, Zhang H, Zhang L, et al. Crp-dependent cytochrome bd oxidase confers nitrite resistance to *Shewanella oneidensis*. *Environ Microbiol*. 2013 Aug;15(8):2198–212. doi:10.1111/1462-2920.12091
53. Borisov VB, Forte E, Siletsky SA, Sarti P, Giuffrè A. Cytochrome bd from *Escherichia coli* catalyzes peroxynitrite decomposition. *Biochim Biophys Acta Bioenerg*. 2015 Feb 2;1847(2):182–8. doi:10.1016/j.bbabi.2014.10.006 PubMed PMID: 25449967.
54. Pudek MR, Bragg PD. Inhibition by Cyanide of the Respiratory Chain Oxidases of *Escherichia coli*. *Arch Biochem Biophys*. 1974;164:682–93.
55. Tsubaki M, Hori H, Mogi T, Anraku Y. Cyanide-binding Site of bd-type Ubiquinol Oxidase from *Escherichia coli**. *J Biol Chem*. 1995;270(48):28565–9.
56. Xia X, Wu S, Li L, Xu B, Wang G. The cytochrome bd complex is essential for chromate and sulfide resistance and is regulated by a GbsR-type regulator, CydE, in *Alishewanella* Sp. WH16-1. *Front Microbiol*. 2018 Aug 10;9(1849). doi:10.3389/fmicb.2018.01849
57. Forte E, Borisov VB, Falabella M, Colaço HG, Tinajero-Trejo M, Poole RK, et al. The Terminal Oxidase Cytochrome bd Promotes Sulfide-resistant Bacterial Respiration and Growth. *Sci Rep*. 2016 Mar 31;6. doi:10.1038/srep23788 PubMed PMID: 27030302.
58. Lu P, Heineke MH, Koul A, Andries K, Cook GM, Lill H, et al. The cytochrome bd-type quinol oxidase is important for survival of *Mycobacterium smegmatis* under peroxide and antibiotic-induced stress. *Sci Rep*. 2015 May 27;5. doi:10.1038/srep10333 PubMed PMID: 26015371.
59. Beebout CJ, Sominsky LA, Eberly AR, Van Horn GT, Hadjifrangiskou M. Cytochrome bd promotes *Escherichia coli* biofilm antibiotic tolerance by regulating accumulation of noxious chemicals. *npj Biofilms Microbiomes*. 2021 Dec 1;7(1). doi:10.1038/s41522-021-00210-x PubMed PMID: 33863914.

60. Seregina TA, Lobanov K V., Shakulov RS, Mironov AS. Inactivation of Terminal Oxidase bd-I Leads to Supersensitivity of *E. coli* to Quinolone and Beta-Lactam Antibiotics. *Mol Biol.* 2022 Aug 1;56(4):572–9. doi:10.1134/S0026893322040100
61. Corbett D, Goldrick M, Fernandes VE, Davidge K, Poole RK, Andrew PW, et al. *Listeria monocytogenes* Has Both Cytochrome bd-Type and Cytochrome aa₃-Type Terminal Oxidases, Which Allow Growth at Different Oxygen Levels, and Both Are Important in Infection. *Infect Immun.* 2017;85:1–13. doi:10.1128/IAI
62. Tran SL, Cook GM. The F₁F₀-ATP synthase of *Mycobacterium smegmatis* is essential for growth. *J Bacteriol.* 2005 Jul;187(14):5023–8. doi:10.1128/JB.187.14.5023–5028.2005 PubMed PMID: 15995221.
63. Cox E, Laessig K. FDA Approval of Bedaquiline — The Benefit-Risk Balance for Drug-Resistant Tuberculosis. *N Engl J Med.* 2014 Aug 21;371(8):689–91. doi:10.1056/nejmp1314385 PubMed PMID: 25140952.
64. Andries K, Verhasselt P, Guillemont J, Göhlmann HWH, Neefs JM, Winkler H, et al. A Diarylquinoline Drug Active on the ATP Synthase of *Mycobacterium tuberculosis*. *Science* (1979). 2005 Jan 14;307.
65. Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. *Nat Chem Biol.* 2007;3(6):323–4. doi:10.1038/nchembio884 PubMed PMID: 17496888.
66. Koul A, Vranckx L, Dendouga N, Bailemans W, Van Den Wyngaert I, Vergauwen K, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. *J Biol Chem.* 2008 Sep 12;283(37):25273–80. doi:10.1074/jbc.M803899200 PubMed PMID: 18625705.
67. Sarathy JP, Gruber G, Dick T. Re-understanding the mechanisms of action of the anti-mycobacterial drug bedaquiline. *Antibiotics.* MDPI AG; 2019. doi:10.3390/antibiotics8040261
68. Saw WG, Wu ML, Ragunathan P, Biuković G, Lau AM, Shin J, et al. Disrupting coupling within mycobacterial F-ATP synthases subunit ϵ causes dysregulated energy production and cell wall biosynthesis. *Sci Rep.* 2019 Dec 1;9(1). doi:10.1038/s41598-019-53107-3 PubMed PMID: 31727946.
69. Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. *Antimicrob Agents Chemother.* 2008 Aug;52(8):2831–5. doi:10.1128/AAC.01204-07 PubMed PMID: 18505852.
70. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. *N Engl J Med.* 2020 Mar 5;382(10):893–902. doi:10.1056/nejmoa1901814 PubMed PMID: 32130813.
71. Nguyen TVA, Anthony RM, Bañuls AL, Vu DH, Alffenaar JWC. Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention. *Clinical Infectious Diseases.* 2018 May 2;66(10):1625–30. doi:10.1093/cid/cix992 PubMed PMID: 29126225.
72. Koul A, Vranckx L, Dhar N, Göhlmann HWH, Özdemir E, Neefs JM, et al. Delayed bactericidal response of *Mycobacterium tuberculosis* to bedaquiline involves remodelling of bacterial metabolism. *Nat Commun.* 2014;5:3369. doi:10.1038/ncomms4369 PubMed PMID: 24569628.
73. Luo M, Zhou W, Patel H, Srivastava AP, Symersky J, Bonar MM, et al. Bedaquiline inhibits the yeast and human mitochondrial ATP synthases. *Commun Biol.* 2020 Dec 1;3(1). doi:10.1038/s42003-020-01173-z PubMed PMID: 32814813.
74. Belosludtsev KN, Belosludtseva N V., Talanov EY, Tenkov KS, Starinets VS, Agafonov A V., et al. Effect of bedaquiline on the functions of rat liver mitochondria. *Biochim Biophys Acta Biomembr.* 2019 Jan 1;1861(1):288–97. doi:10.1016/j.bbmem.2018.06.012 PubMed PMID: 29920239.

75. Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, Krab K, Vergauwen K, Guillemont J, et al. Selectivity of TMC207 towards Mycobacterial ATP synthase compared with that towards the eukaryotic homologue. *Antimicrob Agents Chemother*. 2009 Mar;53(3):1290–2. doi:10.1128/AAC.01393-08 PubMed PMID: 19075053.
76. Tantry SJ, Markad SD, Shinde V, Bhat J, Balakrishnan G, Gupta AK, et al. Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis. *J Med Chem*. 2017 Feb 23;60(4):1379–99. doi:10.1021/acs.jmedchem.6b01358 PubMed PMID: 28075132.
77. Lee BS, Hards K, Engelhart CA, Hasenoehrl EJ, Kalia NP, Mackenzie JS, et al. Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis. *EMBO Mol Med*. 2021 Jan 11;13(1):1–16. doi:10.15252/emmm.202013207 PubMed PMID: 33283973.
78. Shepherd M, Achard MES, Idris A, Totsika M, Phan MD, Peters KM, et al. The cytochrome bd-I respiratory oxidase augments survival of multidrug-resistant Escherichia coli during infection. *Sci Rep*. 2016 Oct 21;6. doi:10.1038/srep35285 PubMed PMID: 27767067.
79. Borisov VB, Siletsky SA, Paiardini A, Hoogewijs D, Forte E, Giuffrè A, et al. Bacterial Oxidases of the Cytochrome bd Family: Redox Enzymes of Unique Structure, Function, and Utility As Drug Targets. *Antioxid Redox Signal*. 2021;34(16):1280–318. doi:10.1089/ars.2020.8039 PubMed PMID: 32924537.
80. Grund TN, Kabashima Y, Kusumoto T, Wu D, Welsch S, Sakamoto J, et al. The cryoEM structure of cytochrome bd from *C. glutamicum* provides novel insights into structural properties of actinobacterial terminal oxidases. *Front Chem*. 2023 Jan 4;10. doi:10.3389/fchem.2022.1085463
81. Safarian S, Rajendran C, Müller H, Preu J, Langer JD, Ovchinnikov S, et al. Structure of a bd oxidase indicates similar mechanisms for membrane integrated oxygen reductases. *Science*. 2016;352(6285):583–6. doi:10.1126/science.aaf2477 PubMed PMID: 27126043.
82. Safarian S, Opel-Reading HK, Wu D, Mehdipour AR, Hards K, Harold LK, et al. The cryo-EM structure of the bd oxidase from *M. tuberculosis* reveals a unique structural framework and enables rational drug design to combat TB. *Nat Commun*. 2021 Dec 1;12(1). doi:10.1038/s41467-021-25537-z PubMed PMID: 34475399.
83. Safarian S, Hahn A, Mills DJ, Radloff M, Eisinger ML, Nikolaev A, et al. Active site rearrangement and structural divergence in prokaryotic respiratory oxidases. *Science*. 2019;366(6461):100–4. doi:10.1126/science.aay0967 PubMed PMID: 31604309.
84. Wang W, Gao Y, Tang Y, Zhou X, Lai Y, Zhou S, et al. Cryo-EM structure of mycobacterial cytochrome bd reveals two oxygen access channels. *Nat Commun*. 2021 Dec 1;12(1). doi:10.1038/s41467-021-24924-w PubMed PMID: 34330928.
85. Friedrich T, Wohlwend D, Borisov VB. Recent Advances in Structural Studies of Cytochrome bd and Its Potential Application as a Drug Target. *International Journal of Molecular Sciences*. MDPI; 2022. doi:10.3390/ijms23063166 PubMed PMID: 35328590.
86. Theßeling A, Rasmussen T, Burschel S, Wohlwend D, Kägi J, Müller R, et al. Homologous bd oxidases share the same architecture but differ in mechanism. *Nat Commun*. 2019 Dec 1;10(1). doi:10.1038/s41467-019-13122-4 PubMed PMID: 31723136.
87. Grauel A, Kägi J, Rasmussen T, Makarchuk I, Oppermann S, Moumbock AFA, et al. Structure of Escherichia coli cytochrome bd-II type oxidase with bound aurachin D. *Nat Commun*. 2021 Dec 1;12(1). doi:10.1038/s41467-021-26835-2 PubMed PMID: 34764272.

88. Murali R, Gennis RB, Hemp J. Evolution of the cytochrome bd oxygen reductase superfamily and the function of CydAA' in Archaea. *ISME Journal*. 2021 Dec 1;15(12):3534–48. doi:10.1038/s41396-021-01019-4 PubMed PMID: 34145390.
89. Theßeling A, Burschel S, Wohlwend D, Friedrich T. The long Q-loop of *Escherichia coli* cytochrome bd oxidase is required for assembly and structural integrity. *FEBS Lett*. 2020 May 1;594(10):1577–85. doi:10.1002/1873-3468.13749 PubMed PMID: 32002997.
90. Goojani HG, Konings J, Hakvoort H, Hong S, Gennis RB, Sakamoto J, et al. The carboxy-terminal insert in the Q-loop is needed for functionality of *Escherichia coli* cytochrome bd-I. *Biochim Biophys Acta Bioenerg*. 2020 Jun 1;1861(5–6). doi:10.1016/j.bbabi.2020.148175 PubMed PMID: 32061652.
91. Grund TN, Radloff M, Wu D, Goojani HG, Witte LF, Jösting W, et al. Mechanistic and structural diversity between cytochrome bd isoforms of *Escherichia coli*. *Proc Natl Acad Sci U S A*. 2021;118(50). doi:10.1073/pnas.2114013118 PubMed PMID: 34873041.
92. Hoerer J, Hong S, Gehmann G, Gennis RB, Friedrich T. Subunit CydX of *Escherichia coli* cytochrome bd ubiquinol oxidase is essential for assembly and stability of the di-heme active site. *FEBS Lett*. 2014 May 2;588(9):1537–41. doi:10.1016/j.febslet.2014.03.036 PubMed PMID: 24681096.
93. Goojani HG, Besharati S, Chauhan P, Asseri AH, Lill H, Bald D. Cytochrome bd-I from *Escherichia coli* is catalytically active in the absence of the CydH subunit. *FEBS Lett*. 2023 Feb 1;597(4):547–56. doi:10.1002/1873-3468.14550 PubMed PMID: 36460943.
94. Wu D, Mehdipour AR, Finke F, Goojani HG, Groh RR, Grund TN, et al. Dissecting the conformational complexity and mechanism of a bacterial heme transporter. *Nat Chem Biol*. 2023 Aug 1;19(8):992–1003. doi:10.1038/s41589-023-01314-5 PubMed PMID: 37095238.
95. Poole RK, Cozens AG, Shepherd M. The CydDC family of transporters. *Res Microbiol*. 2019 Nov 1;170(8):407–16. doi:10.1016/j.resmic.2019.06.003 PubMed PMID: 31279084.
96. Davidson AL, Dassa E, Orelle C, Chen J. Structure, Function, and Evolution of Bacterial ATP-Binding Cassette Systems. *Microbiol Mol Biol Rev*. 2008 Jun;72(2):317–64. doi:10.1128/mmbr.00031-07 PubMed PMID: 18535149.
97. Zhu C, Shi Y, Yu J, Zhao W, Li L, Liang J, et al. Cryo-EM structures of a prokaryotic heme transporter CydDC. *Protein and Cell*. Oxford University Press; 2023. p. 919–23. doi:10.1093/procel/pwado22 PubMed PMID: 37144855.
98. Moosa A, Lamprecht DA, Arora K, Barry CE, Boshoff HIM, Iøerger TR, et al. Susceptibility of *Mycobacterium* Mutants to Compounds Targeting the Terminal Respiratory Oxidase, Cytochrome c. *Antimicrob Agents Chemother*. 2017;61(10):3–7.
99. Mironov A, Seregina T, Shatalin K, Nagornykh M, Shakulov R, Nudler E. CydDC functions as a cytoplasmic cystine reductase to sensitize *Escherichia coli* to oxidative stress and aminoglycosides. *PNAS*. 2007;117(38):23565–70. doi:10.1073/pnas.2007817117/-/DCSupplemental
100. Radloff M, Elamri I, Grund TN, Witte LF, Hohmann KF, Nakagaki S, et al. Short-chain aurachin D derivatives are selective inhibitors of *E. coli* cytochrome bd-I and bd-II oxidases. *Sci Rep*. 2021 Dec 1;11(1). doi:10.1038/s41598-021-03288-7 PubMed PMID: 34903826.
101. Kāgi J, Sloan W, Schimpf J, Nasiri HR, Lashley D, Friedrich T. Exploring ND-011992, a quinazoline-type inhibitor targeting quinone reductases and quinol oxidases. *Sci Rep*. 2023 Dec 1;13(1). doi:10.1038/s41598-023-39430-w PubMed PMID: 37507428.
102. Galván AE, Chalón MC, Schurig-Briccio LA, Salomón RA, Minahk CJ, Gennis RB, et al. Cytochromes bd-I and bo3 are essential for the bactericidal effect of microcin J25 on *Escherichia coli* cells. *Biochim*

- Biophys Acta Bioenerg. 2018 Feb 1;1859(2):110–8. doi:10.1016/j.bbabi.2017.10.006 PubMed PMID: 29107655.
103. Galván AE, Chalón MC, Ríos Colombo NS, Schurig-Briccio LA, Sosa-Padilla B, Gennis RB, et al. Microcin J25 inhibits ubiquinol oxidase activity of purified cytochrome bd-I from *Escherichia coli*. *Biochimie*. 2019 May 1;160:141–7. doi:10.1016/j.biochi.2019.02.007 PubMed PMID: 30790617.
104. Bento CM, Gomes MS, Silva T. Evolution of antibacterial drug screening methods: Current prospects for mycobacteria. *Microorganisms*. MDPI; 2021. doi:10.3390/microorganisms9122562
105. Cai Y, Jaeclein E, Mackenzie J, Papavinasundaram K, Olive AJ, Chen X, et al. Host immunity increases *Mycobacterium tuberculosis* reliance on cytochrome bd oxidase. *PLoS Pathog*. 2021 Jul 1;17(7). doi:10.1371/journal.ppat.1008911 PubMed PMID: 34320028.
106. Gold B, Warriar T, Nathan C. A Multistress Model for High Throughput Screening Against Nonreplicating *Mycobacterium tuberculosis*. In: *Methods in Molecular Biology*. Humana Press Inc.; 2021. p. 611–35. doi:10.1007/978-1-0716-1460-0_27 PubMed PMID: 34235673.
107. Seitz C, Ahn SH, Wei H, Kyte M, Cook GM, Krause KL, et al. Targeting Tuberculosis: Novel Scaffolds for Inhibiting Cytochrome bd Oxidase. *J Chem Inf Model*. 2024 Jul 8;64(13):5232–41. doi:10.1021/acs.jcim.4c00344 PubMed PMID: 38874541.
108. Wu X, Zhang X, Xia W, Zhang Y, Huang K, Zhao F, et al. Discovery of novel Cytochrome bd oxidase inhibitors against *Mycobacterium tuberculosis*. *Eur J Med Chem*. 2025 Nov 15;298. doi:10.1016/j.ejmech.2025.118010
109. Hards K, Cheung CY, Waller N, Adolph C, Keighley L, Tee ZS, et al. An amiloride derivative is active against the F₁F₀-ATP synthase and cytochrome bd oxidase of *Mycobacterium tuberculosis*. *Commun Biol*. 2022 Dec 1;5(1). doi:10.1038/s42003-022-03110-8 PubMed PMID: 35210534.
110. Peterson EJR, Abidi AA, Arrieta-Ortiz ML, Aguilar B, Yurkovich JT, Kaur A, et al. Intricate Genetic Programs Controlling Dormancy in *Mycobacterium tuberculosis*. *Cell Rep*. 2020 Apr 28;31(4). doi:10.1016/j.celrep.2020.107577 PubMed PMID: 32348771.
111. Shi L, Sohaskey CD, Kana BD, Dawes S, North RJ, Mizrahi V, et al. Changes in energy metabolism of *Mycobacterium tuberculosis* in mouse lung and under in vitro conditions affecting aerobic respiration. *Proc Natl Acad Sci U S A*. 2005;102(43):15629–34.
112. Giuffrè A, Borisov VB, Arese M, Sarti P, Forte E. Cytochrome bd oxidase and bacterial tolerance to oxidative and nitrosative stress. *Biochim Biophys Acta Bioenerg*. 2014;1837(7):1178–87. doi:10.1016/j.bbabi.2014.01.016 PubMed PMID: 24486503.
113. Mogi T, Akimoto S, Endou S, Watanabe-Nakayama T, Mizuochi-Asai E, Miyoshi H. Probing the ubiquinol-binding site in cytochrome bd by site-directed mutagenesis. *Biochemistry*. 2006 Jun 27;45(25):7924–30. doi:10.1021/bio60192w PubMed PMID: 16784245.
114. Harikishore A, Mathiyazakan V, Pethe K, Grüber G. Novel targets and inhibitors of the *Mycobacterium tuberculosis* cytochrome bd oxidase to foster anti-tuberculosis drug discovery. *Expert Opin Drug Discov*. 2023;18(8):917–27. doi:10.1080/17460441.2023.2224553 PubMed PMID: 37332221.
115. Kalia NP, Singh S, Hards K, Cheung CY, Sviriaeva E, Banaei-Esfahani A, et al. *M. tuberculosis* relies on trace oxygen to maintain energy homeostasis and survive in hypoxic environments. *Cell Rep*. 2023 May 30;42(5). doi:10.1016/j.celrep.2023.112444 PubMed PMID: 37115669.
116. Cremers CM, Jakob U. Oxidant sensing by reversible disulfide bond formation. *J Biol Chem*. 2013 Sep 13;288(37):26489–96. doi:10.1074/jbc.R113.462929 PubMed PMID: 23861395.

117. Oliveira AR, Mota C, Vilela-Alves G, Manuel RR, Pedrosa N, Fourmond V, et al. An allosteric redox switch involved in oxygen protection in a CO₂ reductase. *Nat Chem Biol.* 2023 Nov 20. doi:10.1038/s41589-023-01484-2
118. Kaurela P, Sharma V, Vonk A, Vattulainen I, Róg T. Distribution and dynamics of quinones in the lipid bilayer mimicking the inner membrane of mitochondria. *Biochim Biophys Acta Biomembr.* 2016;1858(9):2116–22. doi:10.1016/j.bbamem.2016.06.016 PubMed PMID: 27342376.
119. Collins MD, Jones D. Distribution of Isoprenoid Quinone Structural Types in Bacteria and Their Taxonomic Implications. *Microbiol Rev.* 1981;45(2):316–54. doi:10.1128/mr.45.2.316-354.1981
120. Sharma P, Teixeira De Mattos MJ, Hellingwerf KJ, Bekker M. On the function of the various quinone species in *Escherichia coli*. *FEBS J.* 2012 Sep;279(18):3364–73. doi:10.1111/j.1742-4658.2012.08608.x PubMed PMID: 22521170.
121. Borisov VB, Gennis RB, Hemp J, Verkhovsky MI. The cytochrome bd respiratory oxygen reductases. *Biochim Biophys Acta Bioenerg.* 2011 Nov;1807(11):1398–413. doi:10.1016/j.bbabo.2011.06.016 PubMed PMID: 21756872.
122. Lorence RM, Miller MJ, Borochoy A, Faiman-Weinberg R, Gennis RB. Effects of pH and detergent on the kinetic and electrochemical properties of the purified cytochrome d terminal oxidase complex of *Escherichia coli*. *Biochim Biophys Acta.* 1984;790:148. doi:10.1016/0167-4838(84)90218-8
123. Asseri AH, Godoy-Hernandez A, Goojani HG, Lill H, Sakamoto J, McMillan DGG, et al. Cardiolipin enhances the enzymatic activity of cytochrome bd and cytochrome bo₃ solubilized in dodecyl-maltoside. *Sci Rep.* 2021 Dec 1;11(1). doi:10.1038/s41598-021-87354-0 PubMed PMID: 33850195.
124. Upadhyay A, Fontes FL, Gonzalez-Juarrero M, McNeil MR, Crans DC, Jackson M, et al. Partial saturation of menaquinone in mycobacterium tuberculosis: Function and essentiality of a novel reductase, MenJ. *ACS Cent Sci.* 2015 Sep 23;1(6):292–302. doi:10.1021/acscentsci.5b00212
125. Biner O, Fedor JG, Yin Z, Hirst J. Bottom-Up Construction of a Minimal System for Cellular Respiration and Energy Regeneration. *ACS Synth Biol.* 2020 Jun 19;9(6):1450–9. doi:10.1021/acssynbio.0c00110 PubMed PMID: 32383867.
126. Yanofsky DJ, Di Trani JM, Krol S, Abdelaziz R, Bueler SA, Imming P, et al. Structure of mycobacterial CIII₂CIV₂ respiratory supercomplex bound to the tuberculosis drug candidate telacebec (Q203). *Elife.* 2021 Sep 1;10(e71959). doi:10.7554/eLife.71959 PubMed PMID: 34590581.
127. Matsumoto Y, Muneyuki E, Fujita D, Sakamoto K, Miyoshi H, Yoshida M, et al. Kinetic mechanism of quinol oxidation by cytochrome bd studied with ubiquinone-2 analogs. *J Biochem.* 2006 Apr;139(4):779–88. doi:10.1093/jb/mvj087 PubMed PMID: 16672279.
128. Sakamoto K, Miyoshi H, Takegami K, Mogi T, Anraku Y, Iwamura H. Probing substrate binding site of the *Escherichia coli* quinol oxidases using synthetic ubiquinol analogues. *J Biol Chem.* 1996;271(47):29897–902. doi:10.1074/jbc.271.47.29897 PubMed PMID: 8939932.
129. Goddard TD, Huang CC, Meng EC, Pettersen EF, Couch GS, Morris JH, et al. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. *Protein Science.* 2018 Jan 1;27(1):14–25. doi:10.1002/pro.3235 PubMed PMID: 28710774.
130. Sviriaeva E, Subramanian Manimekalai MS, Grüber G, Pethe K. Features and Functional Importance of Key Residues of the Mycobacterium tuberculosis Cytochrome bd Oxidase. *ACS Infect Dis.* 2020 Jul 10;6(7):1697–707. doi:10.1021/acsinfectdis.9b00449 PubMed PMID: 32379966.
131. Kita K, Konishi K, Anraku Y. Terminal oxidases of *Escherichia coli* aerobic respiratory chain. II. Purification and properties of cytochrome b₅₅₈-d complex from cells grown with limited oxygen and

- evidence of branched electron-carrying systems. *J Biol Chem.* 1984;259(5):3375–81. doi:10.1016/S0021-9258(17)43305-9 PubMed PMID: 6321507.
132. Miller MJ, Gennis RB. The Purification and Characterization of the Cytochrome d Terminal Oxidase Complex of the *Escherichia coli* Aerobic Respiratory Chain*. *J Biol Chem.* 1983;258(15):9159–65. doi:10.2558(15):9159-65. PubMed PMID: 6307994.
133. Shestopalov AI, Bogachev A V., Murtazina RA, Viryasov MB, Skulachev VP. Aeration-dependent changes in composition of the quinone pool in *Escherichia coli*. *FEBS Lett.* 1997 Mar 10;404(2–3):272–4. doi:10.1016/S0014-5793(97)00143-9 PubMed PMID: 9119077.
134. Kusumoto K, Sakiyama M, Sakamoto J, Noguchi S, Sone N. Menaquinol oxidase activity and primary structure of cytochrome bd from the amino-acid fermenting bacterium *Corynebacterium glutamicum*. *Arch Microbiol.* 2000;173(5–6):390–7. doi:10.1007/s002030000161 PubMed PMID: 10896219.
135. Jeffreys LN, Ardrey A, Hafiz TA, Dyer LA, Warman AJ, Mosallam N, et al. Identification of 2-Aryl-Quinolone Inhibitors of Cytochrome bd and Chemical Validation of Combination Strategies for Respiratory Inhibitors against *Mycobacterium tuberculosis*. *ACS Infect Dis.* 2023 Feb 10;9(2):221–38. doi:10.1021/acsinfecdis.2c00283 PubMed PMID: 36606559.
136. Li J, Han L, Vallese F, Ding Z, Choi SK, Hong S, et al. Cryo-EM structures of *Escherichia coli* cytochrome bo₃ reveal bound phospholipids and ubiquinone-8 in a dynamic substrate binding site. *Proc Natl Acad Sci U S A.* 2021;118(34). doi:10.1073/pnas.2106750118 PubMed PMID: 34417297.
137. Nikolaev A, Safarian S, Thesseling A, Wohlwend D, Friedrich T, Michel H, et al. Electrocatalytic evidence of the diversity of the oxygen reaction in the bacterial bd oxidase from different organisms. *Biochim Biophys Acta Bioenerg.* 2021 Aug 1;1862(8). doi:10.1016/j.bbabo.2021.148436 PubMed PMID: 33940039.
138. Kao WC, Kleinschroth T, Nitschke W, Baymann F, Neehaul Y, Hellwig P, et al. The obligate respiratory supercomplex from Actinobacteria. *Biochim Biophys Acta Bioenerg.* 2016 Oct 1;1857(10):1705–14. doi:10.1016/j.bbabo.2016.07.009 PubMed PMID: 27472998.
139. Sukheja P, Kumar P, Mittal N, Li SG, Singleton E, Russo R, et al. A novel small-molecule inhibitor of the mycobacterium tuberculosis demethylmenaquinone methyltransferase meng is bactericidal to both growing and nutritionally deprived persister cells. *mBio.* 2017 Jan 1;8(1). doi:10.1128/mBio.02022-16 PubMed PMID: 28196957.
140. Velappan AB, Datta D, Ma R, Rana S, Ghosh KS, Hari N, et al. 2-Aryl benzazole derived new class of anti-tubercular compounds: Endowed to eradicate mycobacterium tuberculosis in replicating and non-replicating forms. *Bioorg Chem.* 2020 Oct 1;103. doi:10.1016/j.bioorg.2020.104170 PubMed PMID: 32890990.
141. Voskuil MI, Bartek IL, Visconti K, Schoolnik GK. The response of *Mycobacterium tuberculosis* to reactive oxygen and nitrogen species. *Front Microbiol.* 2011;2(105). doi:10.3389/fmicb.2011.00105
142. Tur J, Pereira-Lopes S, Vico T, Marín EA, Muñoz JP, Hernández-Alvarez M, et al. Mitofusin 2 in Macrophages Links Mitochondrial ROS Production, Cytokine Release, Phagocytosis, Autophagy, and Bactericidal Activity. *Cell Rep.* 2020 Aug 25;32(8). doi:10.1016/j.celrep.2020.108079 PubMed PMID: 32846136.
143. Small JL, Park SW, Kana BD, Ioerger TR, Sacchettini JC, Ehrt S. Perturbation of cytochrome c maturation reveals adaptability of the respiratory chain in *Mycobacterium tuberculosis*. *mBio.* 2013 Sep 17;4(5):475–88. doi:10.1128/MBIO.00475-13 PubMed PMID: 24045640.

144. Bekker M, De Vries S, Ter Beek A, Hellingwerf KJ, Teixeira De Mattos MJ. Respiration of *Escherichia coli* can be fully uncoupled via the nonelectrogenic terminal cytochrome *bd*-II oxidase. *J Bacteriol.* 2009 Sep;191(17):5510–7. doi:10.1128/JB.00562-09 PubMed PMID: 19542282.
145. Arai H, Kawakami T, Osamura T, Hirai T, Sakai Y, Ishii M. Enzymatic characterization and in vivo function of five terminal oxidases in *Pseudomonas aeruginosa*. *J Bacteriol.* 2014;196(24):4206–15. doi:10.1128/JB.02176-14 PubMed PMID: 25182500.
146. Lu X, Williams Z, Hards K, Tang J, Cheung CY, Aung HL, et al. Pyrazolo[1,5- a]pyridine Inhibitor of the Respiratory Cytochrome *bcc* Complex for the Treatment of Drug-Resistant Tuberculosis. *ACS Infect Dis.* 2019 Feb 8;5(2):239–49. doi:10.1021/acsinfecdis.8b00225 PubMed PMID: 30485737.
147. Heikal A, Nakatani Y, Dunn E, Weimar MR, Day CL, Baker EN, et al. Structure of the bacterial type II NADH dehydrogenase: A monotopic membrane protein with an essential role in energy generation. *Mol Microbiol.* 2014 Mar;91(5):950–64. doi:10.1111/mmi.12507 PubMed PMID: 24444429.
148. Godoy-Hernandez A, Asseri AH, Purugganan AJ, Jiko C, de Ram C, Lill H, et al. Rapid and Highly Stable Membrane Reconstitution by LAIR Enables the Study of Physiological Integral Membrane Protein Functions. *ACS Cent Sci.* 2023 Mar 22;9(3):494–507. doi:10.1021/acscentsci.2c01170
149. Borisov VB, Gennis RB, Hemp J, Verkhovsky MI. The cytochrome *bd* respiratory oxygen reductases. *Biochim Biophys Acta Bioenerg.* 2011;1807(11):1398–413. doi:10.1016/j.bbabbio.2011.06.016 PubMed PMID: 21756872.
150. Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA. CryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination. *Nat Methods.* 2017 Feb 28;14(3):290–6. doi:10.1038/nmeth.4169 PubMed PMID: 28165473.
151. Punjani A, Zhang H, Fleet DJ. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. *Nat Methods.* 2020 Dec 1;17(12):1214–21. doi:10.1038/s41592-020-00990-8 PubMed PMID: 33257830.
152. Sajed T, Marcu A, Ramirez M, Pon A, Guo AC, Knox C, et al. ECMDDB 2.0: A richer resource for understanding the biochemistry of *E. coli*. *Nucleic Acids Res.* 2016;44(D1):D495–501. doi:10.1093/nar/gkv1060 PubMed PMID: 26481353.
153. Friedrich T, Wohlwend D, Borisov VB. Recent Advances in Structural Studies of Cytochrome *bd* and Its Potential Application as a Drug Target. *Int J Mol Sci.* 2022 Mar 1;23(6):3166. doi:10.3390/ijms23063166 PubMed PMID: 35328590.
154. Mascolo L, Bald D. Cytochrome *bd* in *Mycobacterium tuberculosis*: A respiratory chain protein involved in the defense against antibacterials. *Prog Biophys Mol Biol.* 2020 May 1;152:55–63. doi:10.1016/j.pbiomolbio.2019.11.002 PubMed PMID: 31738981.
155. Jones-Carson J, Husain M, Liu L, Orlicky DJ, Vázquez-Torres A. Cytochrome *bd*-dependent bioenergetics and antinitrosative defenses in *Salmonella* pathogenesis. *mBio.* 2016 Jan 1;7(6). doi:10.1128/mBio.02052-16 PubMed PMID: 27999164.
156. Henry SA, Webster CM, Shaw LN, Torres NJ, Jobson ME, Totzke BC, et al. Steroid Drugs Inhibit Bacterial Respiratory Oxidases and Are Lethal Toward Methicillin-Resistant *Staphylococcus aureus*. *J Infect Dis.* 2024 Jul 15;230(1):e149–58. doi:10.1093/infdis/jiad540 PubMed PMID: 39052707.
157. Timkovich R, Cork MS, Gennis RB, Johnson PY. Proposed structure of heme *d*, a prosthetic group of bacterial terminal oxidases. *J Am Chem Soc.* 1985;107(21).
158. Allen RJ, Brenner EP, VanOrsdel CE, Hobson JJ, Hearn DJ, Hemm MR. Conservation analysis of the *CydX* protein yields insights into small protein identification and evolution. *BMC Genomics.* 2014 Dec 5;15(1). doi:10.1186/1471-2164-15-946 PubMed PMID: 25475368.

159. van der Velden TT, Kayastha K, Waterham CYJ, Brünle S, Jeuken LJ.C. Menaquinone-specific turnover by *Mycobacterium tuberculosis* cytochrome bd is redox regulated by the Q-loop disulfide bond. *J Biol Chem.* 2025 Feb;301(2):108094. doi:10.1016/j.jbc.2024.108094
160. Jeuken LJ.C, Connell SD, Nurnabi M, O'Reilly J, Henderson PJF, Evans SD, et al. Direct electrochemical interaction between a modified gold electrode and a bacterial membrane extract. *Langmuir.* 2005 Feb 15;21(4):1481–8. doi:10.1021/la047732f PubMed PMID: 15697298.
161. Weiss SA, Bushby RJ, Evans SD, Jeuken LJ.C. A study of cytochrome bo₃ in a tethered bilayer lipid membrane. *Biochim Biophys Acta Bioenerg.* 2010 Dec;1797(12):1917–23. doi:10.1016/j.bbabbio.2010.01.012 PubMed PMID: 20096262.
162. Jeuken LJ.C, Connell SD, Henderson PJF, Gennis RB, Evans SD, Bushby RJ. Redox enzymes in tethered membranes. *J Am Chem Soc.* 2006 Feb 8;128(5):1711–6. doi:10.1021/jao56972u PubMed PMID: 16448146.
163. Pravda L, Sehnal D, Toušek D, Navrátilová V, Bazgier V, Berka K, et al. MOLEonline: A web-based tool for analyzing channels, tunnels and pores (2018 update). *Nucleic Acids Res.* 2018 Jul 2;46(W1):W368–73. doi:10.1093/nar/gky309 PubMed PMID: 29718451.
164. Janczak M, Vilhjálmssdóttir J, Ädelroth P. Proton transfer in cytochrome bd-I from *E. coli* involves Asp-105 in CydB. *Biochim Biophys Acta Bioenerg.* 2024 Nov 1;1865(4). doi:10.1016/j.bbabbio.2024.149489
165. Yang K, Zhang J, Vakkasoglu AS, Hielscher R, Osborne JP, Hemp J, et al. Glutamate 107 in subunit I of the cytochrome bd quinol oxidase from *Escherichia coli* is protonated and near the heme d/heme b₅₉₅ binuclear center. *Biochemistry.* 2007;46(11):3270–8. doi:10.1021/bio61946+ PubMed PMID: 17305364.
166. Vanorsdel CE, Bhatt S, Allen RJ, Brenner EP, Hobson JJ, Jamil A, et al. The *Escherichia coli* CydX protein is a member of the CydAB cytochrome bd oxidase complex and is required for cytochrome bd oxidase activity. *J Bacteriol.* 2013;195(16):3640–50. doi:10.1128/JB.00324-13 PubMed PMID: 23749980.
167. Richard JP. Protein Flexibility and Stiffness Enable Efficient Enzymatic Catalysis. *J Am Chem Soc.* 2019 Feb 27;141(8):3320–31. doi:10.1021/jacs.8b10836 PubMed PMID: 30703322.
168. Arai H, Kawakami T, Osamura T, Hirai T, Sakai Y, Ishii M. Enzymatic characterization and in vivo function of five terminal oxidases in *Pseudomonas aeruginosa*. *J Bacteriol.* 2014;196(24):4206–15. doi:10.1128/JB.02176-14 PubMed PMID: 25182500.
169. Knetsch TGJ, Ubbink M. The effect of lipid composition on the thermal stability of nanodiscs. *Biochim Biophys Acta Biomembr.* 2024;1866(1):184239. doi:10.1016/j.bbammem.2023.184239 PubMed PMID: 37866687.
170. Boden N, Bushby RJ, Clarkson S, Evans SD, Knowles PF, Marsh A. The Design and Synthesis of Simple Molecular Tethers for Binding Biomembranes to a Gold Surface. *Tetrahedron.* 1997;53(31):10939–52. doi:https://doi.org/10.1016/S0040-4020(97)00698-4
171. Jeuken LJ.C, Daskalakis NN, Han X, Sheikh K, Erbe A, Bushby RJ, et al. Phase separation in mixed self-assembled monolayers and its effect on biomimetic membranes. *Sens Actuators, B.* 2007 Jun 26;124(2):501–9. doi:10.1016/j.snb.2007.01.014
172. Rubinstein JL, Brubaker MA. Alignment of cryo-EM movies of individual particles by optimization of image translations. *J Struct Biol.* 2015 Nov 1;192(2):188–95. doi:10.1016/j.jsb.2015.08.007 PubMed PMID: 26296328.
173. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. *Nature.* 2021 Aug 26;596(7873):583–9. doi:10.1038/s41586-021-03819-2 PubMed PMID: 34265844.

174. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. *Acta Crystallogr D Biol Crystallogr*. 2010;66(4):486–501. doi:10.1107/S0907444910007493 PubMed PMID: 20383002.
175. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, et al. Biological Crystallography PHENIX: building new software for automated crystallographic structure determination. *Acta Crystallographica Section D*. 2002;58.
176. Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. *Protein Science*. 2021 Jan 1;30(1):70–82. doi:10.1002/pro.3943 PubMed PMID: 32881101.
177. Laskowski RA, Swindells MB. LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. *J Chem Inf Model*. 2011 Oct 24;51(10):2778–86. doi:10.1021/ci200227u PubMed PMID: 21919503.
178. Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. *J Chem Inf Model*. 2021 Aug 23;61(8):3891–8. doi:10.1021/acs.jcim.1c00203 PubMed PMID: 34278794.
179. Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem*. 2010 Jan 30;31(2):455–61. doi:10.1002/jcc.21334 PubMed PMID: 19499576.
180. Bugnon M, Röhrig UF, Goullieux M, Perez MAS, Daina A, Michielin O, et al. SwissDock 2024: major enhancements for small-molecule docking with Attracting Cavities and AutoDock Vina. *Nucleic Acids Res*. 2024 Jul 5;52(W1):W324–32. doi:10.1093/nar/gkae300 PubMed PMID: 38686803.
181. Grosdidier A, Zoete V, Michielin O. SwissDock, a protein-small molecule docking web service based on EADock DSS. *Nucleic Acids Res*. 2011 Jul 1;39(SUPPL. 2). doi:10.1093/nar/gkr366 PubMed PMID: 21624888.
182. Aguilar-Pérez C, Lenaerts AJ, Villellas C, Guillemont J, Dallow J, Painter H, et al. The role of cytochrome bc₁ inhibitors in future tuberculosis treatment regimens. *Nat Commun*. 2025 Dec 1;16(1). doi:10.1038/s41467-025-64427-6 PubMed PMID: 41125580.
183. Lu P, Asseri AH, Kremer M, Maaskant J, Ummels R, Lill H, et al. The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd. *Sci Rep*. 2018;8(1):1–7. doi:10.1038/s41598-018-20989-8 PubMed PMID: 29422632.
184. Jones-Carson J, Husain M, Liu L, Orlicky DJ, Vázquez-Torres A. Cytochrome bd-dependent bioenergetics and antinitrosative defenses in *Salmonella* pathogenesis. *mBio*. 2016;7(6). doi:10.1128/mBio.02052-16 PubMed PMID: 27999164.
185. Berney M, Hartman TE, Jacobs WR. A *Mycobacterium tuberculosis* cytochrome bd oxidase mutant is hypersensitive to bedaquiline. *mBio*. 2014 Jul 15;5(4). doi:10.1128/mBio.01275-14 PubMed PMID: 25028424.
186. Li XW, Herrmann J, Zang Y, Grellier P, Prado S, Müller R, et al. Synthesis and biological activities of the respirator chain inhibitor aurachin D and new ring versus chain analogues. *Beilstein J Org Chem*. 2013 Jul 31;9:1551–8. doi:10.3762/bjoc.9.176
187. van der Velden TT, Kayastha K, Pelser F, Brünle S, Jeuken LJ. Visualizing the mechanism of quinol oxidation and inhibition of a bd-type oxidase using cryo-EM. *bioRxiv*. 2025 Oct 10. doi:10.1101/2025.10.10.681541
188. Heinrichs MT, May RJ, Heider F, Reimers T, Sy SKB, Peloquin CA, et al. *Mycobacterium tuberculosis* Strains H37ra and H37rv have equivalent minimum inhibitory concentrations to most antituberculosis drugs. *Int J Mycobacteriol*. 2018 Apr 1;7(2):156–61. doi:10.4103/ijmy.ijmy_33_18 PubMed PMID: 29900893.

189. Franzblau SG, Witzig RS, McLaughlin JC, Torres P, Madico G, Hernandez A, et al. Rapid, Low-Technology MIC Determination with Clinical Mycobacterium tuberculosis Isolates by Using the Microplate Alamar Blue Assay. *J Clin Microbiol.* 1998;36(2):362–6.
190. Sorescu JM, González-Montalvo MA, Yuan M, De Paolo-Boisvert J, Ceapă CD, Garcia-Contreras R, et al. Breakthroughs in the development of antibiotics, antifungals and antiparasitics targeting the pathogens' respiratory chain. *Crit Rev Biochem Mol Biol.* 2025.
191. Krok E, Stephan M, Dimova R, Piatkowski L. Tunable biomimetic bacterial membranes from binary and ternary lipid mixtures and their application in antimicrobial testing. *Biochim Biophys Acta Biomembr.* 2023 Oct 1;1865(7). doi:10.1016/j.bbmem.2023.184194 PubMed PMID: 37328023.
192. Wu D, Mehdi pour AR, Finke F, Goojani HG, Groh RR, Grund TN, et al. Dissecting the conformational complexity and mechanism of a bacterial heme transporter. *Nat Chem Biol.* 2023 Aug 1;19(8):992–1003. doi:10.1038/s41589-023-01314-5 PubMed PMID: 37095238.
193. Zhu C, Shi Y, Yu J, Zhao W, Li L, Liang J, et al. Cryo-EM structures of a prokaryotic heme transporter CydDC. *Protein Cell.* 2023 Dec 1;14(12):919–23. doi:10.1093/procel/pwado22 PubMed PMID: 37144855.
194. Wu D, Mehdi pour AR, Finke F, Goojani HG, Groh RR, Grund TN, et al. Dissecting the conformational complexity and mechanism of a bacterial heme transporter. *Nat Chem Biol.* 2023 Aug 1;19(8):992–1003. doi:10.1038/s41589-023-01314-5 PubMed PMID: 37095238.
195. Aung HL, Berney M, Cook GM. Hypoxia-activated cytochrome bd expression in Mycobacterium smegmatis is cyclic AMP receptor protein dependent. *J Bacteriol.* 2014;196(17):3091–7. doi:10.1128/JB.01771-14 PubMed PMID: 24936051.
196. Cook GM, Membrillo-Hernández J, Hernández H, Poole RK. Transcriptional Regulation of the cydDC Operon, Encoding a Heterodimeric ABC Transporter Required for Assembly of Cytochromes c and bd in Escherichia coli K-12: Regulation by Oxygen and Alternative Electron Acceptors. *J Bacteriol.* 1997;179(20):6525–30.
197. Szklarczyk D, Nastou K, Koutrouli M, Kirsch R, Mehryar F, Hachilif R, et al. The STRING database in 2025: protein networks with directionality of regulation. *Nucleic Acids Res.* 2025 Jan 6;53(D1):D730–7. doi:10.1093/nar/gkae113 PubMed PMID: 39558183.
198. Yamashita M, Shepherd M, Booth WI, Xie H, Postis V, Nyathi Y, et al. Structure and function of the bacterial heterodimeric ABC transporter CydDC: Stimulation of atpase activity by thiol and heme compounds. *Journal of Biological Chemistry.* 2014 Aug 15;289(33):23177–88. doi:10.1074/jbc.M114.590414 PubMed PMID: 24958725.
199. Gerber S, Comellas-Bigler M, Goetz BA, Lochert KP. Structural Basis of Trans-Inhibition in a Molybdate/Tungstate ABC Transporter. *Science* (1979). 2008 Jul 11;321(5886):243–6. doi:10.1126/science.1159292 PubMed PMID: 18556516.
200. Kadaba NS, Kaiser JT, Johnson E, Lee A, Rees DC. The high-affinity E. coli methionine ABC transporter: Structure and allosteric regulation. *Science* (1979). 2008 Sep 7;317(5843):1387–90. doi:10.1126/science.1145950 PubMed PMID: 17673622.
201. Martinez Grundman JE, Schultz TD, Schlessman JL, Liu K, Johnson EA, Lecomte JTJ. Heme d formation in a Shewanella benthica hemoglobin. *J Inorg Biochem.* 2024 Oct 1;259. doi:10.1016/j.jinorgbio.2024.112654 PubMed PMID: 38959524.
202. Murshudov GN, Grebenko AI, Barynin V, Dauter Z, Wilson KS, Vainshtein BK, et al. Structure of the Heme d of Penicillium vitale and Escherichia coli Catalases* From the. *J Biol Chem.* 1996 Apr;271:8863–8.

203. Padayatti PS, Lee SC, Stanfield RL, Wen PC, Tajkhorshid E, Wilson IA, et al. Structural Insights into the Lipid A Transport Pathway in MsbA. *Structure*. 2019 Jul 2;27(7):1114-1123.e3. doi:10.1016/j.str.2019.04.007 PubMed PMID: 31130486.
204. Kong AT, Leprevost F V., Avtonomov DM, Mellacheruvu D, Nesvizhskii AI. MSFragger: Ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics. *Nat Methods*. 2017 Apr 27;14(5):513-20. doi:10.1038/nmeth.4256 PubMed PMID: 28394336.
205. Teo GC, Polasky DA, Yu F, Nesvizhskii AI. Fast Deisotoping Algorithm and Its Implementation in the MSFragger Search Engine. *J Proteome Res*. 2021 Jan 1;20(1):498-505. doi:10.1021/acs.jproteome.0c00544 PubMed PMID: 33332123.
206. Käll L, Canterbury JD, Weston J, Noble WS, MacCoss MJ. Semi-supervised learning for peptide identification from shotgun proteomics datasets. *Nat Methods*. 2007;4(11):923-5. doi:10.1038/nmeth1113 PubMed PMID: 17952086.
207. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. *Anal Chem*. 2003 Sep 1;75(17):4646-58. doi:10.1021/aco341261 PubMed PMID: 14632076.
208. Yu F, Haynes SE, Teo GC, Avtonomov DM, Polasky DA, Nesvizhskii AI. Fast Quantitative Analysis of timsTOF PASEF Data with MSFragger and IonQuant. *Molecular and Cellular Proteomics*. 2020 Sep 1;19(9):1575-85. doi:10.1074/mcp.TIR120.002048 PubMed PMID: 32616513.
209. Luo G, Ono S, Beukes NJ, Wang DT, Xie S, Summons RE. Rapid oxygenation of Earth's atmosphere 2.33 billion years ago. *Sci Adv*. 2016 May 1;2(5). doi:10.1126/sciadv.1600134 PubMed PMID: 27386544.
210. Esposti MD. On the evolution of cytochrome oxidases consuming oxygen. *Biochimica et Biophysica Acta - Bioenergetics*. Elsevier B.V.; 2020. doi:10.1016/j.bbabi.2020.148304 PubMed PMID: 32890468.
211. Hernansanz-Agustín P, Enríquez JA. Alternative respiratory oxidases to study the animal electron transport chain. *Biochim Biophys Acta Bioenerg*. 2023 Jan 1;1864(1). doi:10.1016/j.bbabi.2022.148936 PubMed PMID: 36395975.
212. Baquero F, Levin BR. Proximate and ultimate causes of the bactericidal action of antibiotics. *Nat Rev Microbiol*. 2021 Feb 1;19(2):123-32. doi:10.1038/s41579-020-00443-1 PubMed PMID: 33024310.
213. Kim N, Ripple MO, Springett R. Measurement of the mitochondrial membrane potential and pH gradient from the redox poise of the hemes of the bc₁ complex. *Biophys J*. 2012 Mar 7;102(5):1194-203. doi:10.1016/j.bpj.2012.02.003 PubMed PMID: 22404942.
214. Harrison SH, Walters RC, Cheung CY, Springett RJ, Cook GM, Osman MM, et al. Remission spectroscopy resolves the mechanism of action of bedaquiline within living mycobacteria. *Nat Commun*. 2025 Nov 25. doi:10.1038/s41467-025-65928-0
215. Lakbub JC, Shipman JT, Desaire H. Recent mass spectrometry-based techniques and considerations for disulfide bond characterization in proteins. *Anal Bioanal Chem*. 2018 Apr 1;410(10):2467-84. doi:10.1007/s00216-017-0772-1 PubMed PMID: 29256076.
216. Boersch M, Rudrawar S, Grant G, Zunk M. Menaquinone biosynthesis inhibition: A review of advancements toward a new antibiotic mechanism. *RSC Adv*. 2018;8(10):5099-105. doi:10.1039/c7ra12950e
217. Bagheri S, Haddadi R, Saki S, Kourosh-Arami M, Rashno M, Mojaver A, et al. Neuroprotective effects of coenzyme Q₁₀ on neurological diseases: a review article. *Frontiers in Neuroscience*. Frontiers Media SA; 2023. doi:10.3389/fnins.2023.1188839

218. López-Pedrerá C, Villalba JM, Patiño-Trives AM, Luque-Tévar M, Barbarroja N, Aguirre MÁ, et al. Therapeutic potential and immunomodulatory role of coenzyme q10 and its analogues in systemic autoimmune diseases. *Antioxidants*. MDPI; 2021. doi:10.3390/antiox10040600
219. Król S, Kovalova T, Janczak M, Kalsum S, Akber M, Högbom M, et al. Mycobacterial respiratory chain enzymes and growth are inhibited by decylubiquinone. *Commun Biol*. 2025 Dec 10;9(1):43. doi:10.1038/s42003-025-09309-9
220. Li B, Srivastava S, Shaikh M, Mereddy G, Garcia MR, Chiles EN, et al. Bioenergetic stress potentiates antimicrobial resistance and persistence. *Nat commun*. 2025 Dec 1;16(1). doi:10.1038/s41467-025-60302-6 PubMed PMID: 40490453.
221. Gutierrez A, Jain S, Bhargava P, Hamblin M, Lobritz MA, Collins JJ. Understanding and Sensitizing Density-Dependent Persistence to Quinolone Antibiotics. *Mol Cell*. 2017;68(6):1147-1154.e3. doi:10.1016/j.molcel.2017.11.012 PubMed PMID: 29225037.
222. Arias-Cartin R, Grimaldi S, Pommier J, Lanciano P, Schaefer C, Arnoux P, et al. Cardiolipin-based respiratory complex activation in bacteria. *PNAS*. 2011;108(19):7781-6. doi:10.1073/pnas.1010427108/-/DCSupplemental
223. Klebl DP, Aspinall L, Muench SP. Time resolved applications for Cryo-EM; approaches, challenges and future directions. *Curr Opin Struct Biol*. 2023 Dec 1;83. doi:10.1016/j.sbi.2023.102696 PubMed PMID: 37716094.
224. Li WW, Heinze J, Haehnel W. Site-specific binding of quinones to proteins through thiol addition and addition-elimination reactions. *J Am Chem Soc*. 2005 May 4;127(17):6140-1. doi:10.1021/ja050974X PubMed PMID: 15853297.
225. Chen SH, Li CW. Detection and Characterization of Catechol Quinone-Derived Protein Adducts Using Biomolecular Mass Spectrometry. *Frontiers in Chemistry*. Frontiers Media S.A.; 2019. doi:10.3389/fchem.2019.00571
226. Kovalova T, Janczak M, Gamiz-Hernandez AP, Lundin D, Sharma S, Vilhjálmssdóttir J, et al. The *Mycobacterium smegmatis* bd-II terminal oxidase employs a carboxylate shift mechanism. *BioRxiv*. 2025 Jun 23. doi:10.1101/2025.06.23.660515

